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ABSTRACT 
The natural bioactive compound damnacanthal inhibits several tyrosine kinases. Herein, we 
show that -in fact- damancanthal is a multi kinase inhibitor. A docking and molecular dynamics 
simulation approach allows getting further insight on the inhibitory effect of damnacanthal on 
three different kinases: vascular endothelial growth factor receptor-2, c-Met and focal adhesion 
kinase. Several of the kinases targeted and inhibited by damnacanthal are involved in 
angiogenesis. Ex vivo and in vivo experiments clearly demonstrate that, indeed, damnacanthal 
is a very potent inhibitor of angiogenesis. A number of in vitro assays contribute to determine 
the specific effects of damnacanthal on each of the steps of the angiogenic process, including 
inhibition of tubulogenesis, endothelial cell proliferation, survival, migration and production of 
extracellular matrix remodeling enzyme. Taken altogether, these results suggest that 
damancanthal could have potential interest for the treatment of cancer and other angiogenesis-
dependent diseases. 
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1. Introduction 
 Angiogenesis is a hallmarks of cancer, a crucial step in the transition of tumors from a 
dormant state to a malignant state, and playing an essential role in tumor growth, invasion and 
metastasis [1]. In addition, many non-neoplastic pathologies are related to an upregulated 
angiogenesis [2,3]. For these reasons, there is a current genuine interest in the search for new 
angiogenesis inhibitors as an interesting approach for the treatment of cancer and other 
angiogenesis-dependent diseases. Some antiangiogenic compounds have already been approved 
for the treatment of cancer, blindness and other angiogenesis-dependent diseases [3-5]. 
 Angiogenesis is a complex process that begins in response to an angiogenic stimulus 
with the activation of the normally quiescent endothelial cells. As a consequence, endothelial 
cells undergo a series of phenotypic changes, including the release of proteases that will allow 
them to degrade the basal membrane and subjacent extracellular matrix and migrate. Activated 
endothelial cells can proliferate and avoid apoptosis,  and finally will differentiate forming a 
new capillary. In principle, any compound able to inhibit any of these steps could be a candidate 
for the pharmacological inhibition of angiogenesis [4]. Preclinical and clinical results seem to 
indicate that a multitargeted approach could produce better results in antiangiogenic therapy [6]. 
Our research group actively searches for, identifies and characterizes new natural bioactive 
compounds with multitargeted antiangiogenic effects [7-14]. 
 Damnacanthal (3-hydroxy-1-methoxy-anthraquinone-2-aldehyde, see its chemical 
structure in Figure 1S in supplementary material) is a natural bioactive compound initially 
isolated from the phenolic phase of noni roots, although it is also present in its fruit, as well as 
in other Rubiaceae plants [15,16]. Damnacanthal total synthesis has already  been reported [17]. 
Damnacanthal is characterized as the most potent known selective inhibitor of p56Ick tyrosine 
kinase [18], a protein activity with a key role in the chemotactic response of T cells to CXCL12 
[19]. Additionally, damnacanthal is also able to inhibit other tyrosine kinases (PDGFR, erbB2, 
EGFR and insulin receptor) with IC50 values in the micromolar concentration range [18]. These 
additional effects of damnacanthal could be related to its reported antitumoral effects [20-22]. 
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Very recently, our group has found that damnacanthal is also a potent inhibitor of c-Met and 
behaves as an antitumoral agent against hepatocellular carcinoma [23]. 
 In order to get a deeper insight on the bioactivities of damanacanthal, we have screened 
it against a panel of 25 kinases, showing its potentital as a multi-kinase inhibitor targeting 16 of 
these tested kinases. Docking analysis and molecular dynamics simulations throw new light  on 
this multi-kinase targeting by damnacanthal. Since some of the tyrosine kinases targeted by 
damnacanthal are involved in the regulation of angiogenesis, in the present work we analyze the 
potential of damnacanthal as a new antiangiogenic drug. Our results show for the first time that, 
indeed, damnacanthal inhibits angiogenesis in vitro, ex vivo and in vivo targeting several steps 
of the process. 
 
 
2. Materials and methods 
 
 Supplementary materials and methods (including in vitro kinase inhibition assay, 
docking and molecular dynamics simulations, network and functional enrichment analysis, as 
well as the whole set of in vivo, ex vivo and in vitro assays of angiogenesis, as well as qPCR 
assays with the primers used in this study and listed in Table S1) are included in SI "Materials 
and Methods" (supplementary material). 
 
2.1. Cell culture 
 Bovine aortic endothelial (BAE) cells were isolated from bovine aortic arches as 
previously described [24] and maintained in Dulbecco´s modified Eagle´s medium (DMEM) 
containing glucose (1g/L), glutamine (2mM), penicillin (50 IU/mL), streptomycin (0.05 
mg/mL), and amphotericin (1.25 mg/L) supplemented with 10% FBS (DMEM/10% FBS). 
Human umbilical vein endothelial (HUVE) cells were isolated from umbilical cords as 
previously described [25] and grown on gelatin-coated dishes in Medium 199 containing 10 
mM HEPES, 20% fetal calf serum, glutamine (2 mM) heparin (100 µg/mL) and endothelial cell 
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growth supplement (30 µg/mL). Two immortalized human endothelial cell lines kindly supplied 
by Dr. Arjan W. Griffioen (Maastrich Universtiy,  The Netherlands) were used during this 
study: human umbilical vein endothelial cells (RF-24) and human microvascular endothelial 
cells (HMEC). These immortalized cell lines have been previously characterized [26]. Both 
immortalized human endothelial cell lines were grown in RPMI 1640 medium supplemented 
with glutamine (2mM), penicillin (50 IU/mL), streptomycin (0.05 mg/mL), and amphotericin 
(1.25 mg/L) supplemented with 10% fetal bovine serum, and 10% human serum. Human dermal 
lymphatic microvascular endothelial cells (HMVEC-dLy) were purchased from the American 
Type Culture Collection (ATCC, Rockville, MD, USA). Cells were cultured in EGM-2 MV 
Bullet Kit from Lonza Inc. (Walkersiville, MD, USA) in a humidified atmosphere (5%CO2). 
Cells were passaged upon reaching confluence with Trypsin-EDTA solution. To maintain 
normal growth, hMVEC-dLy cells were used at passage from 3-7 for all experiments. All cell 
cultures were maintained at 37°C under a humidified 5% CO2 atmosphere. 
 
2.2. In vivo angiogenesis assays 
 In this study three different in vivo angiogenesis assays have been used: the 
choriallantoic membrane assay, the Matrigel plug assay and a zebrafish angigoenesis assay. 
Details on how these in vivo assays were performed are provided in SI Materials and Methods. 
 
2.3.Statistical analysis 
 Results are expressed as mean±SD. Statistical significance was determined using the 
two-sided Student t-test. Values of P< 0.05 were considered to be statistically significant. 
 
3. Results 
 
3.1. Damnacanthal inhibits in vitro receptor tyrosine kinases involved in angiogenesis 
 We started our study by carrying out a blind in vitro screening of damnacanthal against 
a panel of 25 kinase activities (see Table S2 in supplementary material). Damnacanthal (10 µM) 
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inhibited more than 50% of the in vitro activity of 16 kinases, including 8 angiogenesis-related 
tyrosine-kinases: VEGFR1-3, FGFR1, 2 and 4, c-Met and EGFR  
 The set of 16 kinases inhibited by damanacanthal was used as a seed to perform simple 
network analysis by using several tools, as described in SI section "Network analysis" 
(supplementary material). The results of this analysis pointed to the involvement of 
damnacanthal in the inhibition of angiogenesis. 
 
3.2. Docking analysis contributes to explain the wide spectrum of damnacanthal as a multi-
kinase inhibitor 
We have used docking and molecular dynamics simulations to determine plausible 
binding modes of damnacanthal into the ATP-binding sites of VEGFR2, FAK and c-Met 
receptors. The selected structures of VEGFR2 and c-Met correspond to the unbound 
phosphorylated state, which resemble the overall conformation and structural features of 
activated kinases [27,28] [29]. In both structures, the active site is accessible after the activation 
loop is ejected upon autophosphorylation of one or more tyrosine residues in its sequence. The 
structure of FAK is  co-crystallized with ATP and corresponds to the unphosphorylated state. 
Nevertheless, the activation loop is also disordered, and the binding site is therefore accessible 
[30]. In all cases, the binding pockets are mostly comprised by hydrophobic residues in the 
glycine-rich loop and hinge region. The inhibitor binds in the same location in all three 
receptors, but its orientation significantly varies between them (see Figure 1). A detailed  
analysis of the structural features of the receptor-inhibitor complexes resulting from the MD 
simulations is provided in SI section " Detailed description and discussion of the docking and 
molecular dynamic results " (supplementary material).  
 
3.3. Damnacanthal inhibits ex vivo and in vivo angiogenesis 
 To analyze the global effects of damnacanthal on angiogenesis, we next made use of an 
ex vivo assay and three in vivo models. 
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 In the ex vivo assay, the capability of new vessel formation from rat aortic ring explants 
was evaluated after 6 and 14 days of incubation in the absence or presence of 12.5 µM 
damnacanthal. Figure 2A shows that in the absence of damnacanthal (controls), aortic rings 
were able to generate a dense microvessel outgrowth in a collagen matrix. In contrast, the 
presence of 12.5 µM damnacanthal completely abrogated this microvessel outgrowth. 
 The chicken chorioallantoic membrane (CAM) assay was selected as our first approach 
to determine the in vivo antiangiogenic activity of damnacanthal because this is a widely used 
and accessible system to study angiogenesis. Figure 2B shows that in untreated CAMs 
(controls), blood vessels form a dense and spatially-oriented branching network of vascular 
structures of decreasing diameter as they branch. The inhibitory effect of damnacanthal is 
revealed by an inhibition of the ingrowth of new vessels in the area covered by the 
methylcelluose disc. In fact, doses as low as 0.5 nmol/disk strongly inhibited angiogenesis 
(decreasing the number of small blood vessels to a 25% of those observed in the areas of control 
CAMs under the control methylcellulose discs without damnacanthal) under the area occupied 
by the methylcellulose disks in half of the tested CAMs.  Furthermore, the peripheral vessels 
(relative to the position of the disk) tended to grow centrifugally, avoiding the treated area, with 
an overall decrease in vascular density and even disruption of preformed vessels within the 
treated area. 
 The in vivo antiangiogenic activity of damnacanthal was confirmed by using the 
intradermal Matrigel plug model. Our results show that this compound caused a strong 
inhibition of the FGF2-mediated cell invasion in the Matrigel plug (Figure 2C). The Matrigel 
plugs without FGF2 were colorless showing their absence of vasculature, whereas the Matrigel 
plugs containing FGF2 were apparently red, due to neovascularization. Matrigels containing 
FGF2 with 50 µM damnacanthal were only partially red, due to a decreased blood vessel 
formation. The hemoglobin contents in the plugs as indicator of neovascularization confirmed 
the inhibitory effect of damnacanthal. 
 The third in vivo experimental approach used to evaluate the effects of damnacanthal on 
angiogenesis was the use of embryos from a transgenic line of zebrafish driving the GFP 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 8 
expression in the endothelium. Throughout the development of the zebrafish embryos, 
intersegmental vessels sprout and grow upward from the aorta, and then, the tips join by 
anastomosis to form a dorsal vein. The lack of formation of the last intersegmental vessels in 
the presence of a test compound is interpreted and accepted as a sign of its antiangiogenic 
effect. Damnacanthal concentrations as low as 1 µM were enough to inhibit the formation of 
some of the last intersegmental blood vessels (Figure 2D). 
 
3.4. Damnacanthal inhibits tubule-like structures formation by endothelial cells grown on 
Matrigel 
 In the screening programs carried out in our lab, test compounds are initially selected by 
their ability to inhibit the formation of "tubule-like" structures by endothelial cells grown on 
Matrigel. This assay simulates the final event of angiogenesis, where endothelial cells form a 
three-dimensional network of new tubes. This is a quantitative and reliable in vitro angiogenesis 
assay that can be adapted for high throughput use [31]. Figure 3A shows representative images 
of controls, as well as damnacanthal treatments at the lowest doses at which there was a 
complete inhibition of the formation of "tubule-like" structures on Matrigel for each endothelial 
cell type tested. For BAEC, we observed signficant inhibitory effects only for 40 µM 
damnacanthal, whereas for human endothelial cells complete inhibition was observed at 20 µM 
damnacanthal in the case of HMEC and at 5 µM damnacanthal in the case of RF-24 cells.  At 
lower concentrations, damnacanthal was able to produce a partial inhibitory effect in a dose-
response manner (Figure 3B).  
 Since one of the kinases targeted by damanacanthal is VEGFR3, which plays a key role 
in lymphangiogenesis, we also wanted to test whether damanacanthal is able to inhibit 
lymphatic vessel formation. Figure 3C shows that damnacanthal is also able to partially inhibit 
the formation of "tubule-like" structures by lymphatic endothelial cell immersed in collagen.  
 Figure 3D shows the effects of damanacanthal added to endothelial cells after the 
formation of "tubule-like" structures on Matrigel. These data suggest that damanacanthal can 
also behave as a vascular disruption agent.  
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3.5. Damnacanthal inhibits endothelial cell proliferation and survival 
 Angiogenesis involves the local proliferation of activated endothelial cells. To 
investigate the ability of damnacanthal to inhibit the growth of serum-activated endothelial 
cells, we made use of the MTT assay. Figure 4A shows that damnacanthal inhibited the growth 
of the three types of endothelial cells tested yielding typical survival curves with half-maximal 
inhibitory concentration values (IC50) within the micromolar range (Table 1). Figure 4B shows 
that damnacanthal was also able to inhibit lymphatic endothelial cell growth (with a IC50 value 
of 31±3 µM), thus reinforcing the afore-mentioned suggestion that damnacanthal can inhibit not 
only angiogenesis but also lymphangiogenesis. 
 Flow cytometric cell cycle analysis of damnacanthal-treated endothelial cells after 
propidum iodide staining allowed detecting significant increases in the apoptotic sub G1 
populations with increasing damnacanthal concentrations (Figure 4C). This effect was 
accompanied by decreases in the G2/M population. The most potent effect was observed in 
BAEC whereas the weakest effects were detected in HMEC (Figure 4C).  
 The proapoptotic effect of damanacanthal on endothelial cells was further demonstrated 
by using the Annexin V/7AAD assay (Figure 5A) and by in vitro determination of caspase 3/7 
activity (Figure 5B). To get some additional insights on specific molecular targets of 
damnacanthal involved  in endothelial cell proliferation and survival, we carried out Western 
blot analysis of proteins extracted from control and damnacanthal-treated HUVEC. ERK1/2 and 
Akt are two of the most relevant signaling pathways controlling endothelial cell proliferatin and 
survival in angiogenesis [32]. Therefore, we examined the effect of 50 µM damnacanthal on the 
HGF-induced phosphorylation of ERK1/2 and Akt in HUVEC. Figure 5C shows a partial 
inhibition of the phosphorylation of both ERK 1 and 2 and a more potent inhibitory effect of 
damnacanthal on the phosphorylation of Akt. 
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3.6. Damnacanthal inhibits endothelial cell attachment to fibronectin  
 During angiogenesis, actively proliferating endothelial cells must migrate into their 
surrounding space by a double action of extracellular matrix (ECM) reearrangement and 
adhesive contacts with components of this ECM. To test whether damnacanthal was able to 
affect endothelial cell adhesion to ECM components, we carried out an adhesion assay on 
fibronectin after 24-h treatment. Figure 6A shows that damnacanthal partially inhibited the 
adhesion of human endothelial cells to fibronectin.  
 Since endothelial cells attach to fibronectin through their integrin a5, we also tested 
whether damnacanthal was able to affect the levels of integrin a5. Figure 6B shows that 
damancanthal decreases the levels of integrin a5, as determined by flow cytometry. 
 
3.7. Damnacanthal inhibits endothelial cell potential to migrate and remodel extracellular 
matrix 
 The scratch "wound healing" assay was used to study the effect of damnacanthal on the 
overall migratory potential of endothelial cells. Figure 7A shows that 50 µM damncanthal was 
able to inhibit partially endothelial cell migration as photografically recorded 7 h after the 
scratch "wounds" were made. The most potent effect were observed on BAEC. Incubations 
were extended up to 24 h after scratch "wounding", a time at which the inhibitory effects of 
damnacanthal were more evident even at concentrations lower than 10 µM (Figure 7B). Figures 
7C and 7D shows that 50 µM damnacanthal also partially inhibited the invasive potential of 
human endothelial cells through a layer of Matrigel in the invasion assay. 
 MMP-2 and uPA are two ECM-remodeling enzymes produced and secreted by 
endothelial cells that play an essential role in angiogenesis allowing the migration and invasion 
of endothelial cells into its surrounding space [33-35]. Gelatin and casein zymographies are 
simple and sensitive techniques to quantify the effects of tested compounds on MMP-2 and uPA 
levels, respectively. Figure 8A shows that damnacanthal is able to inhibit both the production 
and the secretion of BAEC, RF-24 and HMEC endothelial cell MMP-2 in a dose-response 
manner, as determined by the gelatin zymography assay. Quantitative data for results obtained 
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with this assay are provided in Figure 8B. On the other hand, damnacanthal was also able to 
inhibit endothelial cell uPA in a dose-response manner, as determined with both conditioned 
media and cell extracts from HMEC by using a casein zymography assay (see typical results in 
Figure 8C and quantitative data in Figure 8D). Table 2 summarizes data obtained by using 
qPCR to determine the relative levels of expression of mRNAs for MMPs, TIMPs, uPA and 
PAI. These data show that damnacanthal treatment decreased the (MMP-1/2)/TIMP and 
uPA/PAI ratios. 
 
4. Discussion 
 In the present work, we have shown that damnacanthal is an  in vitro inhibitor of several 
tyrosine kinase activities involved in angiogenesis and that damnacanthal effectively inhibits ex 
vivo, in vivo and in vitro angiogenesis.  
It was known that damnacanthal can block T cell chemotaxis [19] through its extremely 
potent inhibition of p56Ick tyrosine kinase activity [18]. However, at concentrations in the 
micromolar range, damnacanthal can also inhibit other tyrosine kinases that are more related to 
cancer, such as PDGFR, erbB2, EGFR and insulin receptor [18]. In fact, several antitumoral 
effects have been previously reported for damnacanthal [20-22]. Our group has added c-Met to 
the list of tyrosine kinases targeted by damnacanthal [23]. Furthermore, several effects of 
damnacanthal on Hep G2 hepatocellular carcinoma suggested that damnacanthal is a new 
inhibitor of c-Met with potential utility for hapatocellular carcinoma treatment [23]. The present 
report confirms the previously described inhibitory effects of damnacanthal on EGFR [20] and 
c-Met [23] and shows that other 6 kinases are also inhibited by damnacanthal: VEGFR1-3 and 
FGFR1, 2 and 4. All these tyrosine kinases are involved in angiogenesis [36,37]. Therefore, the 
anti-angiogenic effects of damnacanthal could be expected. Furthermore, the simple network 
and functional enrichment analyses herein carried out reinforce this suggestion that 
damancanthal could exert anti-angiogenic effects through its targeting of tyrosine kinase 
activities. 
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Tyrosine kinases inhibitors are structurally diverse, but most of them share a common 
mechanism of action based on the inhibition of the catalytic phosphate transfer, by occupying 
the ATP binding site in the protein [38]. The kinase catalytic domain has an overall conserved 
bilobal structure, arranged into two well-differentiated N- and C-terminal domains linked by the 
so-called kinase “hinge” region [27]. ATP binds into the cleft formed between the N- and C-
terminal lobes and interacts with several residues in the hinge region. The docking experiments 
and molecular dynamics simulation performed in this work show a plausible binding mode of 
damnacanthal to the kinase domains of VEGFR2 and c-Met receptors, and FAK. In all three 
cases, the inhibitor is mainly stabilized by hydrophobic interactions with residues in the glycine-
rich loop and ATP-binding site, and by specific interactions with amino acids in the hinge 
region (Figure 1). In summary, our results in docking and molecular dynamic studies show that 
damnacanthal partially occludes the ATP-binding site of the VEGFR2 and c-Met receptors, and 
FAK, and provide structural information of the protein-inhibitor interaction in every case. 
As mentioned above, since these kinases inhibited by damnacanthal are related to 
angiogenesis, the anti-angiogenic effects of damnacanthal could be expected. In fact, this was 
consistently confirmed by four different experimental approaches, an ex vivo and three in vivo 
assays. The ex vivo aortic ring assay recapitulates the events of endothelial cell proliferation, 
migration and the capillary-like tube formation from aortic explants in a collagen matrix [39]. In 
this assay, damnacanthal concentrations ≥12.5 µM completely inhibited angiogenesis. In the 
CAM and zebrafish in vivo angiogenesis assays, damnacanthal behaves as a potent 
antiangiogenic compound at doses and concentrations even lower than those reported for other 
strong angiogenesis inhibitors [7,14,40,41]. In contrast, in the in vivo Matrigel plug assay 50 
µM damnacanthal induced only a partial inhibition of angiogenesis, as previously reported by us 
in the case of aeroplysinin-1 [7].  
 In the present work we have also tested the specific effects of damnacanthal in each of 
the sequential steps of events that take part during the angiogenic process. Potential unspecific 
cytotoxic effects of damnacanthal were discarded in all the in vitro experiments with the 
obvious exception of the cell growth and survival assays by carrying our parallel control assays 
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of in vitro toxicity, as described in the detailed Material and Methods (supplementary material). 
A detailed discusion of the results obtained from in vitro experiments is provided in SI section 
"Detailed discussion of the in vitro results" (supplementary material). These results clearly show 
that damnacanthal affects both the proliferation and survival of endothelial cells, decreases the 
adhesiveness, as well as the migratory and invasive potential of endothelial cells and inhibits the 
final differentiation of endothelial cells to form new vessels. Most of these in vitro experiments 
were carried out with three diffeent types of endothelial cells: primary cultures of boviene aorta 
endothelial cells (BAEC), immortalized human umbilical vein endothelial cells (RF-24) and 
immortalized human microvascular endothelial cells (HMEC). These three types of endothelial 
cells correspond to great, middle and small vessels and exhibited different sensitivities to 
damnacanthal in different in vitro assays. For instance, damnacanthal-treated RF-24 cells 
showed the highest inhibitory effects in the tubulogenesis and the adhesion-to-fibronectin 
assays and in the levels of the MMP-2 extracellular remodeling enzyme. On the other hand, 
BAEC showed the lowest IC50 values in the MTT cell growth assay and the highest counting 
number in the subG1 subpopulation cells. These and other differences in cell type sensitivities 
might suggest some differential specificities for damnacanthal against the angiogenic behavior 
of endothelial cells derived from vessels of different sizes and origins. This posibility deserves 
to be further explored in the future, since its confirmation could have pharmacological interest. 
Some of our in vitro results also suggest that damancanthal could have not only anti-angiogenic 
effects, but could also behave as an anti-lymphangiogenic as well as an anti-vascular compound. 
However, these observations should be taken with caution, since more detailed investigations 
would be required to confirm or refuse these suggestions in a similar way to that used by us and 
others to confirm that toluquinol is an anti-lymphangiogenic compound [42]. 
  In conclusion, taking the obtained results altogether the present work clearly shows that 
damnacanthal behaves as a multikinase inhibitor and a multitargeted antiangiogenic drug, 
suggesting that it could have high potential pharmacological interest for the treatment of 
angiogenesis-dependent diseases, including cancer. Future pre-clinical studies to test its actual 
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therapeutical potential seem warranted. Furthermore, the possibility of defining future synthetic 
derivatives with even better activities and performance deserves to be explored. 
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Table 1⏐ IC50 values. Half-maximal inhibitory concentration (IC50) values 
calculated from dose-response curves as the concentration of compound 
yielding 50% of control cell survival. They are expressed as means ± SD of 
three independent experiments. 
 
  
Cell line IC50 (µM) 
HMEC 46,01 ± 1,42 
RF-24 18,75 ± 0,2 
BAEC 9,88 ± 0,61 
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Table 2⏐ Effects of damnacanthal on the expression levels of extracellular 
matrix proteases and their inhibitors in endothelial cells. Relative 
expression levels of messengers in damnacanthal-treated endothelial cells 
quantified by qPCR are given as percentages with respect to the corresponding 
expression levels in control, untreated cells. Data are means±S.D. of three 
independent experiments. 
 
 
 
 MMP-1 MMP-2 TIMP-1 TIMP-4 uPA PAI-1 
HMEC 38.1 ± 12.4 47.1 ± 5.3 149.6 ± 8.1 167.3 ± 24.1 46.1 ± 10.1 61.1 ± 11.3 
RF-24 2.0 ± 0.1 91.0 ± 1.9 2788.1 ± 240.8 2930.5 ± 1202.0 188.1 ± 22.1  30.4 ± 13.5 
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Figure legends 
Figure 1. Interaction of damnacanthal with the kinase domains of three different 
tyrosine kinases. Final structure of the complexes generated between damnacantal and 
the kinase domains of VEGFR2 (purple), FAK (orange) and c-Met (teal). Receptor 
structures are shown in cartoon whereas damnacantal is shown as spheres. A close-up 
view of the binding pocket is also shown for each system, in which damnacantal is 
depicted as light grey sticks. Key residues in the binding site of each protein are 
highlighted as sticks. 
 
Figure 2. Damnacanthal inhibits angiogenesis ex vivo and in vivo. A) Aortic ring ex 
vivo assay was performed as described in Materials and Methods. Representative 
photographs of aortic rings (lateral view) after 14 days of incubation in a 3D collagen 
gel overlaid with complete medium in the absence (control) or presence of 20 ng/mL 
VEGF, and with 12.5 µM damnacanthal. B) Effect of DC (0.5 nmol/disk) on in vivo 
angiogenesis, as determined by the chorioallantoic membrane (CAM) assay. Areas 
covered by disks are delimited by dashed circles. Arrows point to rebound of vessels 
outward from the treated area. Asterisks indicate disrupted vessels. Experiments were 
carried out as described in Materials and Methods (bar=1000µm). C) Representative 
Matrigel plugs that contained no FGFb, FGFb alone, or FGF plus 50 µM damnacanthal 
were photographed. Total hemoglobin content in the Matrigel plugs was quantified as 
an indicator of blood vessels formation. Data are expressed as means ± SD of at least 
four animals. Symbol indicates significant differences between control- untreated and 
treated cells (*, p < 0.05). D) Inhibition of zebrafish intersegmental vessels by 
damnacanthal. Transgenic TGfli1:EGFPy1 zebrafish embryos, which show green 
fluorescent protein (GFP) expression in endothelial cells, were incubated in the absence 
or presence of damnacanthal. Blood vessel morphology was recorded by fluorescence 
microscopy. Zebrafish intersegmental vessel assay was carried out with different doses 
of damnacanthal, as described in Materials and Methods (bar=50µm). 
Figure 3. Damnacanthal decreases “tubule-like” structures in both endothelial and 
lymphatic cells, and disrupts pre-formed endothelial “tubule-like” structures. A) 
Representative photographs of control (untreated) and damnacanthal-treated endothelial 
cells on Matrigel. B) Quantitative analysis of "tubules" formed in endothelial cells 
treated with 2.5 and 5 µM damnacanthal. C) Representative photographs of control 
(untreated) and damnacanthal-treated lymphatic cells in a collagen matrix. Quantitative 
analysis of data is provided for the full range of tested damnacanthal concentrations in 
lymphatic cells. D) Representative photographs of control (untreated) and 
damnacanthal-treated endothelial cells in the “tubule-like” structure disruption assay. 
Quantitative analysis of data is provided for the full range of tested damnacanthal 
concentrations in endothelial cells. Quantitative data are mean ± SD for three 
independent experiments. Significant differences between control-untreated and treated 
cells: *, p < 0.05; **, p < 0.01; ***, p < 0.005; **** p < 0.001. 
 
Figure 4. Damnacanthal decreases endothelial and lymphatic cells survival. A) 
Survival curve of endothelial cells in the presence of damnacanthal as determined by the 
MTT method. B) Survival curve of lymphatic cells in the presence of damnacanthal as 
determined by the MTT method. C) Effect of damnacanthal on endothelial nuclear 
morphology. Endothelial cells were grown on covers, treated with the indicated 
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concentrations of damnacanthal for 14 h, fixed with formalin, stained with Hoechst, and 
mounted on slides, and nuclei were observed under a fluorescence microscope. D) 
Representative histograms of flow cytometry results of the cell cycle distribution of 
subpopulations of control and damnacanthal-treated endothelial cells after 24 h of 
treatment. Quantitative analysis of cell cycle analysis data for the full range of tested 
compound concentrations. Data are mean ± SD for three independent experiments. 
Significant differences between control-untreated and treated cells: *, p < 0.05. 
 
 
Figure 5. Damnacanthal activates apoptosis mechanism in endothelial cells. A) 
Quantitative analysis of data obtained with the Annexin V/7-AAD apoptosis assay. B) 
Quantitative caspase 3/7 activity in endothelial cells after 24 h of damnacanthal 
treatment. C) Western blot analysis of the effect of 50 µM damnacanthal on p-Akt/Akt 
and p-Erk/Erk ratios in HUVEC. GAPDH levels are used as internal controls. Strips 
corresponding to each of the proteins shown are cropped from different blots run under 
the same experimental conditions.  
Quantitative data are mean ± SD for three independent experiments. Significant 
differences between control-untreated and treated cells: *, p < 0.05; ***, p < 0.005. 
 
 
Figure 6. Damnacanthal decreases adherence ability of endothelial cells. A) 
Representative photographs of control (untreated) and damnacanthal-treated endothelial 
cells on fibronectin-coated plates. Quantitative analysis of data is provided for the full 
range of tested damnacanthal concentrations. B) Histograms represent quantifications of 
the levels of integrin alpha as determined by flow cytometry in HMEC and RF-24 after 
24 h of damnacanthal treatment. Quantitative data are mean ± SD for three independent 
experiments. Significant differences between control-untreated and treated cells: *, p < 
0.05; **, p < 0.01; ***, p < 0.005. 
 
Figure 7.  Damnacanthal decreases endothelial cell migration and invasion. A) 
Representative photographs of endothelial cell migration after 7 h of damnacanthal 
treatment. Quantitative analysis of data for cell-free area is shown in histograms. B) 
Representative photographs of endothelial cell migration after 24 h of damnacanthal 
treatment. Quantitative analysis of data for cell-free area. C-D) Evaluation of invading 
HMEC (C) and RF-24 (D) cells in the invasion assay with untreated and damnacanthal-treated 
cells. Quantitative data are mean ± SD for three independent experiments. Significant 
differences between control-untreated and treated cells: *, p < 0.05; **, p < 0.01; ***, p 
< 0.005. 
 
 
 
Figure 8. Damnacanthal decreased protein levels and gene expression of proteases 
of the extracellular matrix. A) Effect of damnacanthal on the levels of MMP-2 in both 
conditioned media (CM) and cell extracts (CE) from different endothelial cells. 
Representative results of gelatinolytic assays showing the levels of MMP-2 activity in 
control (untreated) and damnacanthal-treated endothelial cells are shown. B) 
Histograms summarize the quantitative analysis of data for the full range of tested 
compound concentrations.  C) Effect of damnacanthal on the levels of uPA activity in 
DC 0 µM DC 3.1 µM DC 50 µMDC 25 µMDC 12.5 µMDC 6.3 µM
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both conditioned media (CM) and cell extracts (CE) from HMEC. Representative 
results of plasminogen zymography assays showing the levels of uPA activity in control 
(untreated) and damnacanthal-treated endothelial cells are shown. D) Histograms 
summarize the quantitative analysis of data for the full range of tested compound 
concentrations. Quantitative data represent mean ± SD for three independent 
experiments. Symbols indicate significant differences between control-untreated and 
treated cells (*, p < 0.05; **, p < 0.01; ***, p < 0.005). 
Figure 6B and 6D legend: 
 
 
 
 
 
 
DC 0 µM DC 3.1 µM DC 50 µMDC 25 µMDC 12.5 µMDC 6.3 µM
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
HIGHLIGHTS 
 
• Damnacanthal inhibits several angiogenesis-related tyrosine kinases. 
• Docking and molecular dynamics provide insights on these inhibitory effects. 
• Damnacanthal is a very potent inhibitor of ex vivo and in vivo angiogenesis. 
• Specific effects of damnacanthal on different angiogenic process steps are shown. 
 
 
